- ≥99% by HPLC per component; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
Tesamorelin + Ipamorelin
Stabilised 44-residue GHRH analogue paired with a selective GHS-receptor agonist
- FormCo-lyophilized powder, sealed glass vial
- Mol. weightTesamorelin: 5135.86 g/mol · Ipamorelin: 711.85 g/mol
- Research areasVisceral adipose tissue models, GH/IGF-1 axis, body composition, lipid metabolism
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
This blend pairs Tesamorelin, a full-length 44-residue analogue of human growth hormone-releasing hormone, with Ipamorelin, a five-residue agonist at the growth hormone secretagogue receptor. Tesamorelin differs from the shorter GHRH fragments used in most secretagogue research: it retains the complete GHRH(1-44) sequence and carries a trans-3-hexenoyl group on the N-terminal tyrosine, a modification that blocks dipeptidyl peptidase-4 cleavage and gives it markedly better stability than unmodified GHRH.
Specifications
Identity
- CAS number
- Tesamorelin: 218949-48-5 · Ipamorelin: 170851-70-4
- Molecular formula
- Tesamorelin: C221H366N72O67S · Ipamorelin: C38H49N9O5
- Molecular weight
- Tesamorelin: 5135.86 g/mol · Ipamorelin: 711.85 g/mol
- Peptide class
- Stabilised full-length GHRH analogue with a growth hormone secretagogue receptor agonist
Supply & purity
- Form
- Co-lyophilized powder, sealed glass vial
- Purity
- ≥99% by HPLC per component; lot-matched COA available
- Available sizes
- 15 mg (10 mg/5 mg), 30 mg (20 mg/10 mg)
- Solubility
- Bacteriostatic water
Additional detail
- Blend ratio
- 2:1 Tesamorelin to Ipamorelin
- Tesamorelin structure
- trans-3-hexenoyl-modified human GHRH(1-44) analogue, 44 residues, C-terminal amide
- Ipamorelin sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Research areas
- Visceral adipose tissue models, GH/IGF-1 axis, body composition, lipid metabolism
- Storage
- Lyophilized: −20 °C, protected from light and moisture. Reconstituted: 2–8 °C, use within the study window.
Questions about Tesamorelin + Ipamorelin
How does Tesamorelin differ from CJC-1295 or Sermorelin?
Sermorelin and CJC-1295 (No DAC) are 29-residue GHRH fragments. Tesamorelin retains the full 44-residue sequence and adds a trans-3-hexenoyl group at the N-terminus that blocks DPP-4 cleavage, giving it substantially better stability and a longer functional window than either fragment.
Why is this blend 2:1 rather than 1:1?
Tesamorelin has a molecular weight roughly seven times that of Ipamorelin, so equal masses would not give comparable molar quantities. The 10 mg/5 mg and 20 mg/10 mg ratios reflect how the pair is typically balanced in research preparations. Each component's mass is stated on the certificate of analysis.
Is each peptide tested independently?
Yes. Purity is established by HPLC and identity by mass spectrometry for each peptide at an independent laboratory before the two are co-lyophilized. The certificate of analysis is matched to the lot number printed on your vial and can be requested at any time.
How should the vial be stored?
Store the sealed lyophilized vial at −20 °C, protected from light and moisture, where it is stable long-term. After reconstitution keep it at 2–8 °C and use within your study window; avoid repeated freeze–thaw cycles and prolonged exposure to room temperature or direct light.
Can this be used in humans?
No. This blend is supplied strictly for in-vitro and laboratory animal research by qualified personnel. It is not a drug, supplement or cosmetic as sold, has no approved use in this form, and must not be administered to humans or animals outside an authorised study. We provide no dosing guidance.
Related
